Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BTCY NASDAQ:CTCX NASDAQ:MDAI NASDAQ:PYPD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBTCYBiotricity$0.54-5.3%$0.46$0.19▼$0.83$13.45M1.1238,059 shs19,072 shsCTCXCarmell$2.58-5.5%$2.96$0.17▼$1.27$53.94M0.514.65 million shs6,324 shsMDAISpectral AI$1.93-3.0%$2.41$0.82▼$3.25$53.19M0.9358,229 shs365,474 shsPYPDPolyPid$3.35-0.9%$3.50$2.30▼$3.93$53.73M1.471,346 shs19,931 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBTCYBiotricity-4.73%+18.75%+52.00%+3.64%+46.15%CTCXCarmell-1.19%+8.33%-30.18%-27.01%+403.60%MDAISpectral AI-5.24%-1.49%-21.03%+24.24%+35.37%PYPDPolyPid-1.17%-2.87%-3.43%+19.01%-3.43%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBTCYBiotricityN/AN/AN/AN/AN/AN/AN/AN/ACTCXCarmellN/AN/AN/AN/AN/AN/AN/AN/AMDAISpectral AI3.1271 of 5 stars3.54.00.00.02.73.30.0PYPDPolyPid3.0061 of 5 stars3.65.00.00.02.71.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBTCYBiotricity 2.00HoldN/AN/ACTCXCarmell 0.00N/AN/AN/AMDAISpectral AI 3.00Buy$3.5081.35% UpsidePYPDPolyPid 3.17Buy$12.40270.15% UpsideCurrent Analyst Ratings BreakdownLatest BTCY, CTCX, PYPD, and MDAI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/14/2025PYPDPolyPidCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $13.008/14/2025PYPDPolyPidRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy8/13/2025PYPDPolyPidHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.006/18/2025PYPDPolyPidRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$12.00 ➝ $9.006/17/2025PYPDPolyPidJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$16.00 ➝ $14.006/9/2025PYPDPolyPidHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$11.00 ➝ $13.006/5/2025PYPDPolyPidRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$9.006/2/2025PYPDPolyPidHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$11.00(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBTCYBiotricity$12.06M1.12N/AN/A($1.30) per share-0.42CTCXCarmell$32.84K1,642.40N/AN/A$1.07 per share2.41MDAISpectral AI$29.58M1.74N/AN/A($0.34) per share-5.68PYPDPolyPidN/AN/AN/AN/A$1.29 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBTCYBiotricity-$14.09M-$0.21N/A∞N/A-80.42%N/A-188.47%11/13/2025 (Estimated)CTCXCarmell-$15.44MN/A0.00∞N/AN/A-217.50%-50.22%N/AMDAISpectral AI-$15.31M-$0.69N/AN/AN/A-51.97%N/A-8.69%11/5/2025 (Estimated)PYPDPolyPid-$29.02M-$3.83N/A∞N/AN/A-453.95%-138.92%11/12/2025 (Estimated)Latest BTCY, CTCX, PYPD, and MDAI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025PYPDPolyPid-$0.53-$0.78-$0.25-$0.78N/AN/A8/12/2025Q2 2025MDAISpectral AI-$0.07-$0.10-$0.03-$0.31$5.44 million$5.07 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBTCYBiotricityN/AN/AN/AN/AN/ACTCXCarmellN/AN/AN/AN/AN/AMDAISpectral AIN/AN/AN/AN/AN/APYPDPolyPidN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBTCYBiotricityN/A0.230.10CTCXCarmellN/A0.310.29MDAISpectral AIN/A0.870.84PYPDPolyPidN/A2.282.28Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBTCYBiotricity3.89%CTCXCarmell24.22%MDAISpectral AI67.08%PYPDPolyPid26.47%Insider OwnershipCompanyInsider OwnershipBTCYBiotricity10.10%CTCXCarmell29.00%MDAISpectral AI30.70%PYPDPolyPid24.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBTCYBiotricity4024.91 million22.08 millionOptionableCTCXCarmell1420.91 million14.84 millionNot OptionableMDAISpectral AI8326.73 million18.53 millionNot OptionablePYPDPolyPid8015.90 million11.97 millionNo DataBTCY, CTCX, PYPD, and MDAI HeadlinesRecent News About These CompaniesRoth Capital Has Negative Outlook for PolyPid Q3 EarningsAugust 19, 2025 | marketbeat.comRoth Capital Issues Negative Forecast for PolyPid EarningsAugust 19, 2025 | americanbankingnews.comShort Interest in PolyPid Ltd. (NASDAQ:PYPD) Declines By 61.0%August 18, 2025 | marketbeat.comResearch Analysts Issue Forecasts for PolyPid Q3 EarningsAugust 17, 2025 | marketbeat.comPolyPid (NASDAQ:PYPD) Rating Lowered to "Sell" at Wall Street ZenAugust 17, 2025 | marketbeat.comPolyPid (NASDAQ:PYPD) Given "Buy" Rating at HC WainwrightAugust 15, 2025 | marketbeat.comPolyPid price target raised to $10 from $9 at Roth CapitalAugust 14, 2025 | msn.comPolyPid Releases Mid-2025 Financial UpdateAugust 14, 2025 | theglobeandmail.comPolyPid Reports Strong Phase 3 Results and Financial UpdateAugust 14, 2025 | msn.comPolyPid Ltd. (NASDAQ:PYPD) Q2 2025 Earnings Call TranscriptAugust 14, 2025 | msn.comPolyPid Ltd (PYPD) Q2 2025 Earnings Call Highlights: Strategic Advances Amid Rising ExpensesAugust 14, 2025 | finance.yahoo.comPolyPid Ltd. (PYPD) Q2 2025 Earnings Call TranscriptAugust 13, 2025 | seekingalpha.comPolyPid sees cash runway ‘well into’ 2026August 13, 2025 | msn.comPolyPid Reports Positive Phase 3 Results and Strengthens LeadershipAugust 13, 2025 | tipranks.comPolyPid Provides Corporate Update and Reports Second Quarter 2025 Financial ResultsAugust 13, 2025 | globenewswire.comPolyPid Ltd.: PolyPid Appoints Dr. Nurit Tweezer-Zaks as Chief Medical OfficerAugust 12, 2025 | finanznachrichten.dePolyPid appoints Tweezer-Zaks as Chief Medical OfficerAugust 12, 2025 | msn.comPolyPid Appoints New Chief Medical Officer Amid Strategic AdvancementsAugust 12, 2025 | msn.comPolyPid Ltd. Appoints Dr. Nurit Tweezer-Zaks as Chief Medical OfficerAugust 12, 2025 | quiverquant.comQPolyPid Appoints Dr. Nurit Tweezer-Zaks as Chief Medical OfficerAugust 12, 2025 | globenewswire.comPolyPid to Report Second Quarter 2025 Financial Results and Operational Highlights on August 13, 2025July 30, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBTCY, CTCX, PYPD, and MDAI Company DescriptionsBiotricity NASDAQ:BTCY$0.54 -0.03 (-5.26%) As of 03:34 PM EasternBiotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.Carmell NASDAQ:CTCX$2.58 -0.15 (-5.49%) As of 08/28/2025Carmell Corporation operates as a bio-aesthetics company. The company utilizes Carmell Secretome to support skin and hair health. Its Carmell Secretome consists of growth factors and proteins extracted from allogeneic human platelets sourced from tissue banks. The company also developed a microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the Foul Fourteen, 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products. In addition, the company is also developing a line of men's products and a line of topical haircare products. It has licensing agreement with Carnegie Mellon University to develop and commercialize biocompatible plasma-based plastics. The company was formerly known as Carmell Therapeutics Corporation and changed its name to Carmell Corporation in November 2023. Carmell Therapeutics Corporation was founded in 2008 and is headquartered in Pittsburgh, Pennsylvania.Spectral AI NASDAQ:MDAI$1.93 -0.06 (-3.02%) Closing price 04:00 PM EasternExtended Trading$2.00 +0.07 (+3.63%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Spectral AI, Inc., an artificial intelligence (AI) company, focuses on developing predictive medical diagnostics in the United States. The company develops medical diagnostics for faster and accurate treatment decisions in wound care with applications involving patients with burns and diabetic foot ulcers. Its products include DeepView System, a predictive analytics platform integrated with the predictive AI-Burn, which combines AI algorithms and multispectral imaging (MSI) imaging for an assessment of wound healing potential and offers clinicians an objective and immediate assessment of a wound's healing potential prior to treatment or other medical intervention; and DeepView SnapShot M, a handheld, portable, and wireless diagnostic tool, that provides a potential enhanced and expanded use for the government and emergency care, first responders, and potentially home health care professionals. The company is headquartered in Dallas, Texas.PolyPid NASDAQ:PYPD$3.35 -0.03 (-0.89%) Closing price 03:59 PM EasternExtended Trading$3.38 +0.03 (+0.90%) As of 06:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It 3 Reasons Gartner Could Be the Best Buy of Q3 NIO Just Got Its Second Upgrade of the Month, and It’s Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access